Cagrilintide 10mg
Cagrilintide Fat-Burning Peptide
Composition: Cagrilintide 10 mg
Class: Peptide
Directions for Use: support for weight loss and appetite control
Dosage form: vial containing 10 mg of lyophilized powder with a separate 1-mL vial of water for injection
Route of administration: subcutaneous injection
- Spedizione (se il prodotto è in stock): 3 giorni lavorativi di processing e dai 5 ai 20 giorni lavorativi di spedizione
- Spese di Processing e spedizione: 27€ in tutta Italia
What is the Cagrilintide
The Cagrilintide It is a peptide designed to promote the reduction of body fat, appetite control, and a lower risk of developing diabetes. Its mechanism of action is based on the activation of the amylin receptors, which are involved in regulating satiety and the rate of gastric emptying.
Unlike receptor agonists GLP-1 (such as semaglutide, tirzepatide, or retatrutide), Cagrilintide acts through a distinct biological pathway. For this reason, it can be used in combination with these medications, especially when they are no longer effective, or by herself, even at lower doses, especially when the goal is to preserve as much muscle mass as possible
Main effects of Cagrilintide
-
Reduces appetite and limits cravings for high-calorie foods
-
Increases the feeling of fullness after meals
-
Slows gastric emptying, prolonging the feeling of fullness
-
Makes it easier to maintain a calorie deficit without persistent hunger
-
Promotes weight loss mainly from body fat
-
Helps preserve muscle mass when combined with training and adequate protein intake
-
Improve food control during periods of strict dieting or competitive training
How to take Cagrilintide
The Cagrilintide It comes in a vial containing 10 mg of freeze-dried powder, which must be reconstituted with water for injection prior to use.
Instead of the standard 1-ml dilution, a dilution with 2 ml of water, in order to make it easier to measure very small doses and reduce the risk of overdose, given the product’s high concentration.
Administration is carried out via subcutaneous injection, once a week, always on the same day.
Recommended weekly schedule
(Dilution: 10 mg of Cagrilintide + 2 mL of water for injection).
| Weeks | Weekly dose | Notes |
|---|---|---|
| 1–4 | 0.3 mg | Initial dose – assess tolerance |
| 5–8 | 0.6 mg | Increase only if well tolerated |
| 9–12 | 1.2 mg | Gradual increase |
| 16 | 1.8 mg | For those who need a more pronounced effect |
| 17+ | 2.4 mg | Maximum dose – do not exceed |
If you miss a dose:
-
Take it as soon as possible if there are more than 3 days until the next one.
-
If there are less than 3 days left, skip the missed dose.
When used in combination with GLP-1 medications, it is recommended that Do not increase the doses at the same time: First stabilize one, then increase the other after 1–2 weeks.
Precautions
-
Avoid use if you have a known allergy to any of the ingredients.
-
Use caution if you have never taken similar therapy before.
-
Avoid in the presence of severe gastrointestinal disorders.
-
In diabetic patients, it may be necessary to adjust hypoglycemic therapy.
-
Monitor blood sugar and general condition during the first few weeks
Possible side effects
-
Nausea (more common at the beginning)
-
Mild abdominal bloating or discomfort
-
Constipation or diarrhea
-
Headache
-
Fatigue
-
Rarely allergic reactions
Storage
-
Store the freeze-dried powder between 2 °C and 8 °C
-
After reconstitution, store in a refrigerator (2–8 °C).
-
Do not freeze
-
Protect from direct light
How Cagrilintide works
Relationship with amylin
Cagrilintide is a synthetic analog of amylin, a hormone naturally released by the pancreas during meals. Its function is to signal to the brain that food has been ingested and to slow down digestion.
Effect on the stomach
After injection, Cagrilintide binds to specific receptors in the brain that send a signal to the stomach to slow down. Food remains in the stomach longer, prolonging satiety in a physiological and safe manner.
Neural signals of satiety
The drug amplifies the natural “fullness” signals transmitted to the hypothalamus, reducing hunger pangs and delaying the return of appetite.
Energy balance
Cagrilintide helps the body better manage the balance between calories consumed and calories burned, promoting more stable and efficient energy use.
Clinical studies and combination with GLP-1
Cagrilintide acts through a different mechanism than GLP-1 drugs. The combination of these two mechanisms produces a double signal of fullness, proving to be particularly effective.
Phase 2 and 3 clinical trials have shown that the combination Cagrilintide + semaglutide can lead to an average weight loss of 20–23% in 68 weeks, with results comparable to or better than those of the best drugs currently available.
Frequently asked questions (FAQ)
Is Cagrilintide legal?
It is still in the clinical trial phase and is not available in pharmacies, but it can be used for research purposes.
Does it cause you to lose muscle mass?
Not directly. Muscle loss depends on how quickly you lose weight and on your diet. Adequate protein intake and strength training help preserve muscle mass.
Does it cause cancer?
There is currently no evidence linking Cagrilintide to cancer. The available studies do not show such a risk.
You must be logged in to post a review.













Reviews
There are no reviews yet.